Palivizumab cuts number of days of wheezing in preemies

May 9, 2013
Palivizumab cuts number of days of wheezing in preemies
For preterm infants, administration of the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection is associated with a significant reduction in the number of days of wheezing during the first year of life, according to a study published in the May 9 issue of the New England Journal of Medicine.

(HealthDay)—Many pre-term babies suffer recurrent episodes of wheezing. Now, researchers say a common infection is a likely culprit and they may be able to prevent the breathing problems.

Wheezing episodes in late pre-term babies often are caused by infection with the respiratory synctial virus (RSV), the researchers said. And they've found that injections of an expensive RSV medication can prevent the virus—and the wheezing.

A study of more than 400 babies born late pre-term (between 33 and 35 weeks' gestation) found that days with wheezing dropped by more than 60 percent among those who received injections of palivizumab during RSV season. The effect lasted even after treatment ended.

"In pre-term babies, RSV illnesses seem to be a risk factor for wheezing, and this treatment reduced that risk," said Dr. Robert Lemanske Jr., a professor of pediatrics and medicine at the University of Wisconsin School of Medicine and Public Health, in Madison. Lemanske wrote an editorial accompanying the new study, which was published May 9 in the New England Journal of Medicine.

RSV is a global health threat in the first year of life and the second leading cause of death after malaria, said study lead author Dr. Louis Bont, a pediatric infectious disease specialist at the University Medical Center Utrecht in the Netherlands.

"The risk of hospitalization for RSV bronchiolitis in otherwise healthy late pre-term [babies] is 5 percent," Bont said. "For other pre-terms, it is higher. About half of all otherwise healthy late pre-terms develop wheezing illness."

RSV-related wheezing reduces quality of life, and it has been linked to the development of asthma, Bont said. It's not yet clear if using palivizumab to prevent RSV will lower rates of asthma, he added.

RSV season lasts about four to five months during the fall, winter or spring, but the exact timing in the United States varies by region, according to the U.S. Centers for Disease Control and Prevention. There is no vaccine for the virus, which causes only mild symptoms in adults and older children.

The study was funded by Abbott Laboratories and the Netherlands Organization for Health Research and Development. Abbott markets palivizumab in some foreign countries.

The researchers set out to determine if RSV was the cause of wheezing illness
during the first year of life. Studying 429 babies in the Netherlands, they randomly assigned half to receive a monthly injection of palivizumab during RSV season. The other half received a placebo drug.

The babies in the treatment group had 61 percent fewer days of wheezing during the first year of life. This led the researchers to conclude that RSV is a likely contributor to wheezing illness in this group of children.

The study also found that 21 percent of the babies who received no treatment had recurrent wheezing, compared to 11 percent in those receiving palivizumab. The number of infants who needed medication to treat their wheezing was also less in the palivizumab group, according to the study.

Other than redness and swelling at the injection site, the drug is very well tolerated, Bont said.

The reduction in wheezing comes at a price, however. A season's treatment would likely reach about $10,000 in the United States, Bont said, adding that cost varies from country to country. A child's weight, which determines dosage, also affects the cost of treatment.

"Society needs to define whether its cost-effectiveness is acceptable," Bont said. He said palivizumab should be a standard preventive treatment for premature infants during RSV season.

Lemanske agreed that this is a very expensive intervention. "But if wheezing episodes in pre-term infants are associated with significant [illnesses], then preventing RSV could translate into dollars and cents too," he said. "Whether this will reduce disease risk down the road remains to be seen."

Explore further: Study offers clues to making vaccine for infant respiratory illness

More information: Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

Study offers clues to making vaccine for infant respiratory illness

April 25, 2013
An atomic-level snapshot of a respiratory syncytial virus (RSV) protein bound to a human antibody represents a leap toward developing a vaccine for a common—and sometimes very serious—childhood disease. The findings, ...

New study finds maternal diet important predictor of severity for infant RSV

March 4, 2013
An important predictor of the severity of respiratory syncytial virus (RSV) in infants may be what their mothers ate during pregnancy, according to a Vanderbilt study published in the American Journal of Respiratory and Critical ...

Research suggests transmission of respiratory viruses in utero

April 18, 2013
The most common cause of lower respiratory tract infections in infants and young children, respiratory syncytial virus (RSV), can be transferred during pregnancy to an unborn baby, according to Cleveland Clinic Children's ...

Vitamin C may head off lung problems in babies born to pregnant smokers

May 4, 2013
Pregnant women are advised not to smoke during pregnancy because it can harm the baby's lungs and lead to wheezing and asthma, among other problems. If a woman absolutely can't kick the habit, taking vitamin C during pregnancy ...

Massage therapy may enhance immunity in preterm infants

November 13, 2012
(HealthDay)—For stable, preterm infants, daily massage therapy (MT) is positively associated with higher natural killer (NK) cell cytotoxicity and weight gain, according to a study published online Nov. 12 in Pediatrics.

Study examines neurodevelopmental outcomes for children born extremely preterm

April 30, 2013
Fredrik Serenius, M.D., Ph.D., of Uppsala University, Uppsala, Sweden, and colleagues conducted a study to assess neurological and developmental outcome in extremely preterm (less than 27 gestational weeks) children at 2.5 ...

Recommended for you

Study reveals how MRSA infection compromises lymphatic function

January 17, 2018
Infections of the skin or other soft tissues with the hard-to-treat MRSA (methicillin-resistant Staphylococcus aureus) bacteria appear to permanently compromise the lymphatic system, which is crucial to immune system function. ...

Newly-discovered TB blood signal provides early warning for at-risk patients

January 17, 2018
Tuberculosis can be detected in people with HIV infection via a unique blood signal before symptoms appear, according to a new study by researchers from the Crick, Imperial College London and the University of Cape Town.

Fresh approach to tuberculosis vaccine offers better protection

January 17, 2018
A unique platform that resulted in a promising HIV vaccine has also led to a new, highly effective vaccine against tuberculosis that is moving toward testing in humans.

New study offers insights on genetic indicators of COPD risk

January 16, 2018
Researchers have discovered that genetic variations in the anatomy of the lungs could serve as indicators to help identify people who have low, but stable, lung function early in life, and those who are particularly at risk ...

Previous influenza virus exposures enhance susceptibility in another influenza pandemic

January 16, 2018
While past exposure to influenza A viruses often builds immunity to similar, and sometimes different, strains of the virus, Canadian researchers are calling for more attention to exceptions to that rule.

Don't hold your nose and close your mouth when you sneeze, doctors warn

January 15, 2018
Pinching your nose while clamping your mouth shut to contain a forceful sneeze isn't a good idea, warn doctors in the journal BMJ Case Reports.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.